ID: ALA122998

Max Phase: Preclinical

Molecular Formula: C17H15N5S

Molecular Weight: 321.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1c(Sc2cccc3ccccc23)[nH]c2nc(N)nc(N)c12

Standard InChI:  InChI=1S/C17H15N5S/c1-9-13-14(18)20-17(19)22-15(13)21-16(9)23-12-8-4-6-10-5-2-3-7-11(10)12/h2-8H,1H3,(H5,18,19,20,21,22)

Standard InChI Key:  FHGCNTCLPBNZQO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 321.41

Molecular Weight (Monoisotopic): 321.1048

AlogP: 3.74

#Rotatable Bonds: 2

Polar Surface Area: 93.61

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.34

CX Basic pKa: 8.36

CX LogP: 3.91

CX LogD: 2.93

Aromatic Rings: 4

Heavy Atoms: 23

QED Weighted: 0.52

Np Likeness Score: -0.64

References

1. Gangjee A, Lin X, Queener SF..  (2004)  Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.,  47  (14): [PMID:15214795] [10.1021/jm0306327]

2. Shah K, Lin X, Queener SF, Cody V, Pace J, Gangjee A..  (2018)  Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.,  26  (9): [PMID:29691153] [10.1016/j.bmc.2018.04.032]

Source

Source(1):

• Scientific Literature